Search

everythinglearnresearchcommunity

for

Search:↓

The document concludes that diagnosing PCOS in teenagers is difficult and should focus on specific hormone levels and menstrual irregularities, while also considering treatment for symptoms and related health issues.

Dihydrotestosterone causes p27 protein breakdown in ovarian and breast cancer cells by binding with SKP2.

Women with AGA have more androstenedione and dihydrotestosterone, less copper and zinc; copper imbalance affects AGA; treatment improves hormones and minerals.

Obese women had more testosterone and less acne, but similar hair growth compared to non-obese women.

The document concludes that proper diagnosis and tailored long-term treatment can effectively manage androgenic disorders in women, improving patient care outcomes.

Primary care for PCOS focuses on lifestyle changes, medication based on symptoms, and mental health, with diabetes screening and specialist referral for severe cases.

A certain gene variant may increase the risk of polycystic ovary syndrome in Chinese women.

The document concludes that a systematic approach is crucial to identify causes of androgen excess in women beyond the most common cause, Polycystic ovary syndrome (PCOS).

Menopausal acne is treated with medications and lifestyle changes, but careful choice is needed due to side effects.

The document concludes that treating female hair loss should target reducing excess androgen and blocking its effects on hair follicles, with the best treatments being hormonal therapy, adrenal suppression, and topical minoxidil.

Women with low SHBG levels and a high 3a-diol G to SHBG ratio are likely to experience female pattern baldness, possibly due to a slight excess of androgens affecting sensitive hair bulbs.

Excessive hair growth in women can be harmless or signal serious health issues, and treatment often includes medication and hair removal, with noticeable results after 3-6 months.

A postmenopausal woman's hirsutism and high testosterone levels improved after surgery for an ovarian tumor not seen on ultrasound.

Testosterone therapy can modestly improve sexual function in menopausal women but should be used cautiously and is not recommended for routine measurement in sexual dysfunction or hirsutism.

Low-dose anti-androgen drugs and certain drug combinations are effective for hirsutism, and insulin sensitizers show promise, especially for those with polycystic ovarian syndrome.

The new compounds moderately block a specific enzyme and strongly counteract a male hormone, suggesting potential for treating certain male-related health conditions.

New hormonal treatments for enlarged prostate show promise for safer, effective non-surgical options.

High androgen levels cause skin issues in PCOS, affecting quality of life.

Most women with excessive hair growth have PCOS; treatment varies and focuses on preventing new hair, with electrolysis as the only permanent removal method.

PCOS is a major cause of infertility and requires personalized treatment.

A woman was the first known case to have both polycystic ovary syndrome and autoimmune polyglandular syndrome type 2, suggesting a need to check for both conditions in similar patients.

Hirsutism in women is often due to hormone sensitivity and has significant psychological effects.

Current research explores hair growth drugs, while future research aims for personalized treatments.

Flutamide, an antiandrogen, has minimal impact on female rat endocrine systems and does not significantly change their reproductive cycles.

AGA in children needs careful diagnosis due to low androgen levels and possible other causes.

Finasteride negatively affects fish reproduction and gonadal development.

Different drugs can treat high male hormone levels in women, but they have various effects and some may harm a fetus.

Androgens contribute to common male hair loss; more research needed for hair growth medication.

Androgen and Wnt signals are crucial for developing and functioning male genitalia and erectile tissues.

Research from 2011 to 2020 shows androgen receptors could be key for prognosis and treatment in certain breast cancers.